SPAGNOLO, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.353
AS - Asia 3.125
EU - Europa 1.976
SA - Sud America 889
AF - Africa 782
OC - Oceania 90
Continente sconosciuto - Info sul continente non disponibili 26
Totale 14.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.959
SG - Singapore 1.001
BR - Brasile 658
HK - Hong Kong 658
CN - Cina 438
IT - Italia 341
VN - Vietnam 211
FI - Finlandia 177
PL - Polonia 176
DE - Germania 173
FR - Francia 110
RU - Federazione Russa 105
SE - Svezia 93
NL - Olanda 88
GB - Regno Unito 86
AT - Austria 56
IN - India 54
CI - Costa d'Avorio 51
MX - Messico 49
AR - Argentina 48
TR - Turchia 48
EC - Ecuador 38
KR - Corea 38
IE - Irlanda 34
IQ - Iraq 34
ZA - Sudafrica 32
ES - Italia 31
TW - Taiwan 30
UZ - Uzbekistan 30
KE - Kenya 28
VE - Venezuela 28
CR - Costa Rica 27
KZ - Kazakistan 27
AL - Albania 26
AM - Armenia 26
GE - Georgia 26
GT - Guatemala 26
ID - Indonesia 26
AO - Angola 25
BY - Bielorussia 25
CH - Svizzera 25
DO - Repubblica Dominicana 25
EE - Estonia 25
JM - Giamaica 25
SI - Slovenia 25
EG - Egitto 24
JP - Giappone 24
LB - Libano 24
MD - Moldavia 24
SA - Arabia Saudita 24
UG - Uganda 24
IR - Iran 23
LA - Repubblica Popolare Democratica del Laos 23
PK - Pakistan 23
TH - Thailandia 23
TN - Tunisia 23
ZM - Zambia 23
AZ - Azerbaigian 22
CA - Canada 22
GM - Gambi 22
HN - Honduras 22
ME - Montenegro 22
NP - Nepal 22
TZ - Tanzania 22
UA - Ucraina 22
BF - Burkina Faso 21
CU - Cuba 21
LU - Lussemburgo 21
MU - Mauritius 21
RS - Serbia 21
TT - Trinidad e Tobago 21
BD - Bangladesh 20
BO - Bolivia 20
DK - Danimarca 20
DZ - Algeria 20
HU - Ungheria 20
IS - Islanda 20
LV - Lettonia 20
MK - Macedonia 20
MN - Mongolia 20
MR - Mauritania 20
MY - Malesia 20
MZ - Mozambico 20
NI - Nicaragua 20
PS - Palestinian Territory 20
SN - Senegal 20
AU - Australia 19
BE - Belgio 19
BS - Bahamas 19
CO - Colombia 19
KG - Kirghizistan 19
ML - Mali 19
PE - Perù 19
PG - Papua Nuova Guinea 19
YT - Mayotte 19
AE - Emirati Arabi Uniti 18
BA - Bosnia-Erzegovina 18
CG - Congo 18
GH - Ghana 18
LY - Libia 18
Totale 13.407
Salva come PNG Salva come JPEG
Città #
Fairfield 1.236
Ashburn 752
Woodbridge 651
Hong Kong 640
Singapore 599
Ann Arbor 477
Houston 462
Seattle 436
Cambridge 370
Chandler 344
Wilmington 323
Boardman 192
Beijing 159
Bytom 145
San Diego 114
Medford 107
Princeton 106
Santa Clara 94
Ho Chi Minh City 80
Los Angeles 80
Munich 79
Des Moines 71
Helsinki 68
São Paulo 61
Hefei 58
Dong Ket 50
Abidjan 47
Buffalo 46
Roxbury 45
Padova 39
Turku 38
Hanoi 31
Vienna 31
New York 30
Dublin 29
Nuremberg 29
Tashkent 27
Chicago 26
Redondo Beach 26
Nairobi 25
Seoul 25
Milan 24
Kampala 23
Lusaka 23
London 22
Rome 22
Baku 21
Havana 21
Luanda 21
Rio de Janeiro 21
Tallinn 21
Dakar 20
Managua 20
Ulan Bator 20
Bishkek 19
Brooklyn 19
Johannesburg 19
Podgorica 19
Vientiane 19
Dushanbe 18
Lappeenranta 18
Port Moresby 18
Amman 17
Antananarivo 17
Bamako 17
Dallas 17
Dar es Salaam 17
Guatemala City 17
Harare 17
Nanjing 17
Nouakchott 17
Reykjavik 17
San José 17
Tbilisi 17
Yerevan 17
Accra 16
Kingston 16
Libreville 16
Nassau 16
Noumea 16
Bangkok 15
Ljubljana 15
Praia 15
Belo Horizonte 14
Brasília 14
Conakry 14
Dili 14
Guangzhou 14
Kigali 14
Minsk 14
Padua 14
Riga 14
Salvador 14
Bridgetown 13
Cairo 13
Council Bluffs 13
Gaborone 13
Guayaquil 13
Kinshasa 13
Montevideo 13
Totale 9.253
Salva come PNG Salva come JPEG
Nome #
High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment 213
Immune inflammation and disease progression in idiopathic pulmonary fibrosis 189
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) 169
High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology 167
Abandoning developmental silos: what can paediatricians and adult interstitial lung disease physicians learn from each other? 164
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 153
The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease 141
Critical review of the evolution of extracellular vesicles’ knowledge: From 1946 to today 139
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH 137
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies 132
CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline 132
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 130
Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis 129
Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis 127
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives 126
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis 125
Research highlights from the 2018 ERS International Congress: interstitial lung diseases 124
A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients 124
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 122
Accuracy of individual in the monitoring of long term change in pulmonary sarcoidosis as judge by serial HRCT data 121
The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis 121
Clinical Features and Chest Imaging as Predictors of Intensity of Care in Patients with COVID-19 120
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy 119
Immunogenetics of Disease-Causing Inflammation in Sarcoidosis 118
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: A pooled analysis 118
Matriptase, protease-activated receptor 2, and idiopathic pulmonary fibrosis: Further evidence for signaling pathway redundancy in this difficult-to-treat disease? 118
Interstitial lung disease in children younger than 2 years 118
Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy 117
Sarcoidosis: a Critical Review of History and Milestones 116
Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications 116
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 116
Differential diagnosis of usual interstitial pneumonia: When is it truly idiopathic? 115
Update on therapeutic management of idiopathic pulmonary fibrosis 115
New guideline on treatment of idiopathic pulmonary fibrosis 115
Chickenpox-Related Multiple Pulmonary Granulomas: A Poorly Recognized Entity 113
Imaging aspects of the diagnosis of sarcoidosis 113
Brief communication: Chest radiography score in young COVID-19 patients: Does one size fit all? 112
Idiopathic pulmonary fibrosis: An update 112
Pharmacological management of IPF 112
IPF in 2016: towards a better diagnosis 112
RNA Sequencing of Epithelial Cell/Fibroblastic Foci Sandwich in Idiopathic Pulmonary Fibrosis: New Insights on the Signaling Pathway 112
An important step forward, but still a way to go 111
Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield 110
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy 109
Disease Severity and Prognosis of SARS-CoV-2 Infection in Hospitalized Patients Is Not Associated With Viral Load in Nasopharyngeal Swab 109
Diagnosis and Management of Asthma - The Swiss Guidelines 108
Characterization of pulmonary function in 10–18 year old patients with Duchenne muscular dystrophy 108
Association between leukocyte telomere length (LTL) and functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF) on antifibrotic treatment 108
Biopsy in idiopathic pulmonary fibrosis: back to the future 106
Hemoptysis and progressive dyspnea in a 67-year-old woman with history of renal transplantation 105
Pharmacological treatment of idiopathic pulmonary fibrosis: An update 104
Connective tissue diseases, multimorbidity and the ageing lung 104
Novel Treatments for Idiopathic Pulmonary Fibrosis 104
Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials 101
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis 101
The Diagnostic Yield of the Multidisciplinary Discussion in Patients With COVID-19 Pneumonia 101
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future 100
Daily home spirometry: A new milestone in the field of pulmonary fibrosis 100
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 99
Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD) 98
Genetic determinants of pulmonary fibrosis: Evolving concepts 97
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis 97
Classification of different patterns of pulmonary adenocarcinomas 97
Pulmonary sarcoidosis 97
Recurrent cerebrospinal fluid basophilia in neurosarcoidosis 96
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment 96
Massive lung calcifications in a four times renal transplanted patient: the fight against dialysis, hyper and hypoparathyroidism 96
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome 95
Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy 94
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities 94
Patients with IPF and lung cancer: diagnosis and management 93
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis 93
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 93
Pharmacological treatment of idiopathic pulmonary fibrosis: An update 92
Genetics of idiopathic pulmonary fibrosis: From mechanistic pathways to personalised medicine 92
Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review 91
Genetics of sarcoidosis 90
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study 90
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development 88
The role of macrophages in interstitial lung diseases 87
Pulmonary fibrosis secondary to COVID-19: a call to arms? 87
The management of patients with idiopathic pulmonary fibrosis 86
Acute exacerbations of interstitial lung disease: Lessons from idiopathic pulmonary fibrosis 85
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 85
Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia 84
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis 84
Large cell neuroendocrine carcinoma of the lung: chemotherapy regimen depends on how "large" your diagnostic criteria are 83
Hypersensitivity pneumonitis: A comprehensive review 82
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy 82
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone 82
Chest x-ray or CT for COVID-19 pneumonia? Comparative study in a simulated triage setting 82
Symptomatic smokers without COPD have physiological changes heralding the development of COPD 80
The immunopathogenesis of sarcoidosis 79
The role of bronchoscopy in the diagnosis and management of patients with sars-cov-2 infection 78
Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study 78
Shedding light on developmental drugs for idiopathic pulmonary fibrosis 77
Clinical trial research in focus: why do so many clinical trials fail in IPF? 76
Arrhythmias in Cardiac Sarcoidosis Bench to Bedside: A Case-Based Review 76
The value of chest radiograph and computed tomography in pulmonary sarcoidosis 75
Pleural clinic: where thoracic ultrasound meets respiratory medicine 73
Totale 10.760
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.504
article - articoli 52.622
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.126
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.107 0 0 59 60 24 24 239 71 184 234 105 107
2021/20221.517 62 126 235 75 120 75 61 193 146 43 95 286
2022/2023810 184 18 22 86 163 97 1 52 139 6 34 8
2023/2024702 18 86 70 50 51 77 53 45 28 37 109 78
2024/20253.499 12 217 135 117 320 68 192 251 423 199 666 899
2025/20264.070 653 1.393 2.024 0 0 0 0 0 0 0 0 0
Totale 14.522